This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks. The primary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks adjunctive to insulin treatment can reduce body weight in patients with T1D and overweight or obesity when compared to insulin treatment alone. The secondary objective is to demonstrate that tirzepatide treatment, dose incremented to 15mg QW for 32 weeks can improve glycaemic control (measured by hbA1c), improve time in range, reduce insulin requirements, and reduce the severity of comorbidities in people with obesity and T1D. This trial includes a 6 month follow-up period.

Start Date30 Nov 2026

Sponsor / Collaborator

Royal North Shore Hospital

NCT07468552

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)

The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.

Start Date14 Nov 2026

Sponsor / Collaborator

National Institute on Drug Abuse

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

1,901

Literatures (Medical) associated with Tirzepatide

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study

Article

Author: Zimner-Rapuch, Sarah ; Annemans, Lieven ; van Hest, Naomi ; Johansson, Erin ; Wilding, John P. H. ; Grist, Josephine ; Spaepen, Erik

PURPOSE:

This study presents an updated health economic model for evaluating the long-term cost-effectiveness of interventions in overweight and obesity, integrating new clinical evidence from the SURMOUNT clinical trial programme and methodological advancements in type-2 diabetes and obstructive sleep apnea (OSA) modelling.

PATIENTS AND METHODS:

An updated individual patient simulation model evaluated the costs and long-term clinical outcomes of tirzepatide (5, 10, 15.0 mg) versus diet and exercise (D&E) alone in patients with a body mass index (BMI) ≥30 kg/m² (obesity), or BMI ≥27 to <30 kg/m² (overweight) + ≥1 obesity-related complication with a UK healthcare perspective. Key improvements over a previously published model were introduced, including modelling remission and progression of OSA, capturing realistic patterns of D&E discontinuation, incorporating HbA1c as a continuous cardiometabolic endpoint and transition to R-based implementation over VBA. Primary results include incremental cost-effectiveness ratios (ICERs; cost/QALY), costs, life years gained and quality-adjusted life years (QALYs). Secondary outcomes including clinical outcomes, random seed and cohort convergence, deterministic sensitivity results and run time were also calculated.

RESULTS:

The refined model predicted that all tirzepatide doses were cost-effective compared to D&E at a £20,000/QALY gained WTP (willingness-to-pay) threshold (ICERs: £8,327-£10,157). Refined estimation of long-term D&E discontinuation and OSA remission likely contributed to lower incremental costs, higher QALYs, and reduced ICERs compared with the previous model, aligning outcomes more closely with expected benefits from weight management treatment. Transitioning to R-based implementation reduced run time (e.g. by 4.52 h for deterministic sensitivity analyses) and enhanced model stability in all analyses conducted.

CONCLUSION:

This enhanced economic model represents a significant advancement in the evaluation of obesity pharmacotherapy, designed to enhance clinical relevance, technical robustness, and increase usability. It supports evidence-based decision-making for chronic weight management treatment in the UK, and beyond, while offering a scalable platform for future therapeutic evaluations.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK

Article

Author: Kanumilli, Naresh ; Evans, Jerome ; Cattin, Juliette ; Debackere, Nele ; Osumili, Beatrice ; Buckingham, Mike ; Hunt, Barnaby ; Webb, Joanne ; Nowakowski, Piotr

INTRODUCTION:

Tirzepatide is a treatment for type 2 diabetes associated with improvements in glycemic control and weight loss, and a low risk of hypoglycemia when not used in combination with insulin or insulin secretagogues. A cost to target analysis of tirzepatide 5, 10 and 15 mg versus subcutaneous semaglutide 1 mg in the UK setting was performed, calculating the annual pharmacy cost per patient treated to six composite endpoints combining glycemic control (glycated hemoglobin [HbA1c] ≤ 6.5% [48 mmol/mol] and <7.0% [53 mmol/mol]) with weight loss (≥5%, ≥10%, ≥15%) and avoidance of hypoglycemia. The costing analysis was based on the tirzepatide costs appraised by NICE as part of TA924.

METHODS:

The proportions of patients achieving composite treatment targets with tirzepatide and semaglutide (both in combination with metformin) were taken from a post-hoc analysis of the SURPASS-2 clinical trial (N = 1,845). Costs per patient treated to target were calculated by dividing the annual treatment costs associated with each intervention by the proportion of patients achieving the treatment target with each intervention.

RESULTS:

Tirzepatide 5, 10 and 15 mg were associated with a lower pharmacy cost per patient achieving treatment target than semaglutide 1 mg for the majority of endpoints evaluated. Differences became greater at more strict treatment targets. For example, the cost per patient achieving HbA1c ≤6.5%, weight loss ≥15%, and no hypoglycemia was GBP 5,650, GBP 8,665 and GBP 9,462 lower with tirzepatide 5, 10 and 15 mg, respectively, compared with semaglutide 1 mg over a 1-year time horizon. The only endpoint where semaglutide 1 mg was associated with a lower cost per patient achieving target was HbA1c <7.0%, weight loss ≥5%, and no hypoglycemia.

CONCLUSIONS:

Compared to semaglutide, tirzepatide was associated with a lower annual pharmacy cost per patient with diabetes achieving treatment target in the UK for the majority of endpoints, with greater differences at more strict treatment targets.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial

Article

Author: Zimner-Rapuch, Sarah ; Kirk, Myles ; Johansson, Erin ; van Hest, Naomi ; Annemans, Lieven ; Bays, Harold ; Wilding, John P. H. ; Spaepen, Erik ; Upadhyay, Navneet

PURPOSE:

This study evaluated the cost-effectiveness (from the United States [US] societal perspective) of tirzepatide at its maximum-tolerated-dose (MTD) compared to semaglutide (MTD), both administered adjunct to a reduced-calorie diet and increased physical activity. The analysis focused on individuals with obesity (body mass index [BMI] ≥ 30 kg/m²), or overweight (BMI ≥27 to <30 kg/m² + ≥1 obesity-related complication), using data from the head-to-head Phase-3 SURMOUNT-5 trial (patients without type 2 diabetes [T2D]).

PATIENTS AND METHODS:

This patient-level simulation modeling study assessed the cost and long-term clinical outcomes of tirzepatide (MTD) versus semaglutide (MTD), using data from the SURMOUNT-5 trial population. The modeled population were at risk of developing obesity-related complications including cardiovascular disease (CVD) and obstructive sleep apnea (OSA), amongst others. These outcomes were modeled using cardiometabolic parameters including weight, systolic blood pressure, high-density lipoprotein, glycated hemoglobin (HbA1c) and total cholesterol, by assessing their impact on healthcare and wider societal costs, quality of life, and mortality. Incremental cost-effectiveness ratios (ICERs; cost/quality-adjusted life year [QALY]) and incremental net health benefit (iNHBs) were calculated, and uncertainty was assessed through sensitivity and scenario analyses.

RESULTS:

Tirzepatide (MTD) was estimated to be less costly and more efficacious compared to semaglutide (MTD) with per patient cost savings of $41,688, 0.506 QALYs gained and positive iNHB of 0.784, indicating a net health benefit for tirzepatide. The model predicted that per 1,000 patients, 70 fewer patients will develop T2D, 10 fewer will develop CVD with tirzepatide (MTD) and patients spend 3.07 more years living with moderate/severe OSA when treated with semaglutide (MTD).

CONCLUSION:

Based on this simulation model, using head-to-head SURMOUNT-5 trial data, tirzepatide (MTD) had lower total costs and higher QALYs compared to semaglutide (MTD). This supports that tirzepatide (MTD) is a cost-effective treatment option for individuals with obesity or overweight compared to semaglutide (MTD).

1,861

News (Medical) associated with Tirzepatide

27 May 2026

·www.novonordisk.com

Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions

Plainsboro, NJ, US and Bagsværd, Denmark, 27 May 2026 – Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association ® (ADA), taking place in New Orleans, June 5–8, 2026. Phase 3 REIMAGINE 1–3 results evaluating the effects of investigational CagriSema on glycemic control and weight loss across a range of type 2 diabetes background therapies will be featured in an ADA Scientific Session. 1 A total of 40 abstracts will be presented, including phase 2 data assessing the safety and efficacy of investigational once-weekly injectable zenagamtide, as well as new data for Ozempic ® and Wegovy ® , building on the growing body of clinical evidence for semaglutide across multiple cardiometabolic conditions. 2 “The ADA’s 2026 Scientific Sessions underscores the breadth and strength of our approach to cardiometabolic diseases. From amylin-based pipeline candidates to continued expansion of our portfolio, we are building on the established and unique profile of semaglutide,” said Martin Holst Lange, executive vice president of Research & Development and chief scientific officer at Novo Nordisk. “As pioneers in this space, we remain focused on advancing innovation that can meaningfully improve the lives of millions living with serious chronic diseases.” On Sunday, 7 June 2026, Novo Nordisk will host an R&D investor event on the science and abstracts presented at the conference. The event will be accessible via a live webcast on the Novo Nordisk investor website . Select Novo Nordisk abstracts to be presented at The ADA’s 2026 Scientific Sessions, 5-8 June, New Orleans: Data for investigational uses of semaglutide and investigational medicines containing CagriSema, zenagamtide, IcoSema, and efruxifermin. Symposium: • REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema – Sunday, 7 June; 4:30–6:00 pm CDT Novo Nordisk poster and oral presentations: CagriSema Zenagamtide Wegovy ® (semaglutide injection and tablets) Ozempic ® (semaglutide injection and tablets) Semaglutide for MASH Insulin Icodec • 1750-P Glucodynamics and Hypoglycemia Risk During Exercise or Fasting in Individuals with T2D Receiving Once-Weekly Basal Insulin Icodec – Saturday, 6 June; 12:30–1:30 pm CDT IcoSema Efruxifermin • 1294-OR Efruxifermin Improved Liver Disease and Insulin Sensitivity in Participants with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis in the SYMMETRY Trial – Monday, 8 June; 2:45–3:00 pm CDT Cross-product • 1696-P Effect of Semaglutide on COVID-19-Related Complications and All-Cause Death: Pooled Analyses of the SELECT, FLOW, and SOUL Trials – Sunday, 7 June; 12:30–1:30 pm CDT Non-product 9 additional abstracts being presented at ADA will cover data related to cardiometabolic diseases, including type 2 diabetes, obesity, kidney, and liver disease. CagriSema, zenagamtide, IcoSema, and efruxifermin are not approved in the United States. Safety and efficacy are not established, and there is no guarantee that these investigational medicines will become commercially available for the uses under clinical investigation. About semaglutide Semaglutide is a GLP-1 receptor agonist (GLP-1 RA) that is structurally similar to the naturally occurring hormone GLP-1. It works by selectively binding to and activating the GLP-1 receptor. Semaglutide has been tested in several robust clinical development programs and outcome studies in cardiometabolic diseases, including type 2 diabetes, obesity, cardiovascular disease, heart failure, chronic kidney disease, liver disease, and other related cardiometabolic diseases. Semaglutide is marketed under the brand names Wegovy ® (semaglutide) injection 2.4 mg, Wegovy ® HD (semaglutide) injection 7.2 mg, Wegovy ® (semaglutide) tablets 25 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg, and Ozempic ® (semaglutide) tablets 4 mg or 9 mg. About CagriSema CagriSema is being investigated by Novo Nordisk as a once-weekly subcutaneous injectable treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program). CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide. 1 About zenagamtide Zenagamtide, formerly known as amycretin, is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Zenagamtide is under investigation for oral and subcutaneous administration. About type 2 diabetes Type 2 diabetes is a chronic condition that affects how the body processes blood sugar (glucose) for energy. 3 According to 2023 CDC data, in the United States, 40.1 million people have diabetes, with type 2 diabetes representing 90% to 95%, or an estimated 36 – 38 million people living with type 2 diabetes, making it the most common form of the disease. 3,4 About obesity Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. 5-7 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. 5,7 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment. 8,9 About Novo Nordisk Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 67,900 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in seven states plus Washington, D.C. For more information, visit novonordisk.com and novonordiskus.com, and follow us on Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information: References © 2026 Novo Nordisk All rights reserved. US26SEMO01000 May 2026

Phase 2Drug ApprovalPhase 3

26 May 2026

·www.biospace.com

MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions

Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate presentation at Sachs Associates Annual Obesity & Cardiometabolic Innovation Forum Harwell, Oxford, UK – 27 May 2026 : MitoRx Therapeutics (“MitoRx”), a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity, announces that preclinical data for its lead asset MTRX31 will be presented at the American Diabetes Association’s 2026 Scientific Sessions (ADA 2026), taking place in New Orleans, Louisiana from 5-8 June. The poster will disclose data on weight loss induced by MTRX31 in diet-induced obesity (DIO) mice, an industry-standard preclinical model of obesity. MTRX31 is a novel small molecule that aims to eliminate ectopic fat from affected organs by resetting mitochondrial function rather than suppressing appetite, restoring healthy mitochondrial metabolism by resetting the balance between fat and carbohydrate oxidation. Poster presentation details: Title: Myo-004 (MTRX31) induces bodyweight loss in DIO at thermoneutrality by switching metabolism from fat to carbohydrate oxidation Presenter: Xavier Jacq, Chief Scientific Officer, MitoRx Therapeutics Authors: Xavier Jacq, Roberta Torregrossa, Thais Rouquet, Julien Roux, Rick Cousins, Norman Law, Jonathan Rees Date/Time: Sunday 7 June 2026, 12.30pm – 1.30pm CDT Location: Poster Hall, Ernest N. Morial Convention Center, New Orleans, Louisiana In addition to the poster presentation at ADA 2026, MitoRx’s Chief Scientific Officer Xavier Jacq will attend the Sachs Associates 2 nd Annual Obesity & Cardiometabolic Innovation Forum (OCIF), taking place on 5 June 2026 in New Orleans, where he will participate in a panel titled ‘ Platform Technologies Panel: Obesity & Cardiovascular-Kidney-Metabolic Disease’ from 11.40am – 12.30pm CDT. Xavier will also deliver a corporate presentation at 2.20pm CDT on 5 June 2026 at Sachs OCIF. - Ends - About MitoRx Therapeutics MitoRx is a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity. This is critical for the 30-40% of patients living with metabolically unhealthy obesity – characterized by visceral adiposity and insulin resistance involving mitochondrial dysfunction – who are at disproportionate risk of metabolic-associated fatty liver disease, metabolic-associated steatohepatitis, type 2 diabetes and atherosclerotic cardiovascular disease. Our first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs by resetting mitochondrial function rather than suppressing appetite. This has the potential to deliver durable and higher quality weight loss, with implications for lower risk of cardiovascular complications and other serious diseases, as well as benefits for body composition and improved quality of life. Preclinical studies showed high-dose MTRX31 driving significant weight loss that outperformed tirzepatide in magnitude, quality and durability after only two months of treatment. Find out more about our work on LinkedIn or visit our website at mitorxtherapeutics.com . For more information about MitoRx Therapeutics, please contact: MitoRx Therapeutics info@mitorxtherapeutics.com ICR Healthcare Tracy Cheung, Ashley Tapp, Phillip Marriage mitorx@icrhealthcare.com

26 May 2026

·www.biospace.com

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in individuals with obesity with or without Type 2 Diabetes Mellitus (T2DM) - Longer exposure to ARO-INHBE silencing resulted in continued improvements in visceral fat and liver fat from Week 12 to Week 24 PASADENA, Calif.--(BUSINESS WIRE)-- $arwr -- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The data presented at the European Association for the Study of the Liver Congress (EASL 2026) demonstrate that ARO-INHBE treatment led to clinically meaningful reductions in liver fat as a monotherapy and in combination with low-dose tirzepatide, a GLP-1/GIP receptor co-agonist, in adults with obesity. Arrowhead is currently engaging with regulatory authorities on additional designs and endpoints for potential Phase 2 studies in MASH and obesity. “Building on prior interim results from a Phase 1/2a study of ARO-INHBE, which showed encouraging signals on weight loss and improved measures of body composition in obese patients with diabetes, today we presented additional results at the EASL 2026 congress. These data provide encouraging signals on the safety, activity, and efficacy of ARO-INHBE, particularly with respect to liver fat reductions as a monotherapy or in combination with low-dose tirzepatide in patients with or without Type 2 Diabetes Mellitus,” said James Hamilton, M.D., MBA, Chief Medical Officer and Head of R&D at Arrowhead. “We believe that targeting the Activin E/ALK7 pathway, a genetically validated pathway that regulates adipose fat storage, is a promising strategy to address MASH and obesity‑related metabolic dysfunction and may complement existing incretin-based approaches in the treatment of obesity.” The EASL 2026 poster may be accessed on the Events and Presentations page on the Investors section of the Arrowhead website. Select ARO-INHBE Phase 1/2a Results In participants with obesity, dose-dependent reductions in Activin E were observed following a single administration of ARO-INHBE, with a mean maximum reduction of 85.3% achieved with ARO-INHBE 400 mg and persistent effect beyond 3 months Similar Activin E reductions were observed in participants with obesity and T2DM receiving two doses of ARO-INHBE (200 mg or 400 mg) in combination with tirzepatide 5 mg, demonstrating persistent effect through Week 24 with the potential for infrequent twice per year dose administration Participants with obesity and baseline liver fat content (LFC) greater than 8% receiving 200mg or greater of ARO-INHBE monotherapy (n=10; baseline LFC 14.5±5.1%) had a placebo-adjusted post-dose LFC reduction of 44% (t-test: p < 0.01) ARO-INHBE in combination with low-dose tirzepatide (5 mg) resulted in enhanced reductions in visceral adipose tissue and LFC compared to tirzepatide alone in participants with obesity with or without T2DM Longer exposure to ARO-INHBE resulted in continued improvements in visceral fat and LFC from Week 12 to Week 24 Safety and Tolerability ARO-INHBE has been generally well tolerated to date as a monotherapy and in combination with tirzepatide in participants with obesity with and without type 2 diabetes. Most treatment emergent adverse events (TEAE) were mild in severity. No TEAEs led to study or study drug discontinuation. Injection site reactions were generally mild and self-limited. About ARO-INHBE ARO-INHBE is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. INHBE is a promising genetically validated target in which loss-of-function INHBE variants in humans are associated with improved fat distribution and lower risk of metabolic diseases, such as type 2 diabetes. Activin E acts as a ligand in a pathway that regulates energy homeostasis in adipose tissue. Inhibiting this pathway with investigational ARO-INHBE treatment has the potential to increase lipolysis, and reduce adipose hypertrophy and dysfunction, visceral adiposity, and insulin resistance. About the AROINHBE-1001 Phase 1/2 Study AROINHBE-1001 ( NCT06700538 ) is a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-INHBE in up to 78 adult volunteers with obesity. Part 1 of the study is designed to assess single and multiple doses of ARO-INHBE monotherapy, and Part 2 of the study is designed to assess ARO-INHBE in combination with tirzepatide, a subcutaneously administered GLP-1/GIP receptor co-agonist that has been approved in the United States and the European Union for management of type 2 diabetes mellitus since 2022 and weight management since 2023/2024 respectively. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve. For more information, please visit , or follow us on X (formerly Twitter) at @ArrowheadPharma , LinkedIn , Facebook , and Instagram . To be added to the Company's email list and receive news directly, please visit . Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc. Contacts Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 ir@arrowheadpharma.com Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 britchie@lifesciadvisors.com Media: LifeSci Communications, LLC Kendy Guarinoni, Ph.D. 724-910-9389 kguarinoni@lifescicomms.com

Clinical ResultPhase 2siRNA

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	Tirzepatide	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity Hypoventilation Syndrome	China	Eli Lilly Suzhou Pharmaceutical Co. Ltd.	30 Jun 2025
Sleep Apnea, Obstructive	United States	Eli Lilly & Co.	20 Dec 2024
Obesity	United States	Eli Lilly & Co.	08 Nov 2023
Overweight	United States	Eli Lilly & Co.	08 Nov 2023
Weight Gain	Australia	Eli Lilly Australia Pty Ltd.	23 Dec 2022
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart failure with normal ejection fraction	NDA/BLA	China	Eli Lilly & Co.	22 Nov 2024
Reduced ejection fraction co-occurrent and due to chronic heart failure	NDA/BLA	European Union	Eli Lilly & Co.	-
Metabolic dysfunction-associated steatotic liver disease	Phase 3	United States	Eli Lilly & Co.	16 Oct 2025
Colitis, Ulcerative	Phase 3	United States	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Austria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Belgium	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Brazil	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Bulgaria	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Canada	Eli Lilly & Co.	26 Jun 2025
Colitis, Ulcerative	Phase 3	Czechia	Eli Lilly & Co.	26 Jun 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06588296 (TOGETHER-PsA, Pubmed \| Arthritis Rheumatol)	Phase 3	Arthritis, Psoriatic	271	Ixekizumab + Tirzepatide	anfrthlpjt(rjhejhhpfn) = jhqqibzhus ftrcmynxsp (wnhbfcfzwc ) View more	Positive	28 Mar 2026
				Ixekizumab	anfrthlpjt(rjhejhhpfn) = jjzzqzdzfc ftrcmynxsp (wnhbfcfzwc ) View more
NCT04255433 (Pubmed \| JAMA Cardiol)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus, Type 2	13,165	Tirzepatide	vnszjoibbt(agwddeumjq) = ucovitnnzq egpjzipcyx (zifcspinrz ) View more	Positive	28 Mar 2026
				Dulaglutide	vnszjoibbt(agwddeumjq) = jnwxtctrog egpjzipcyx (zifcspinrz ) View more
NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obes Pillars)	Phase 3	Obesity	4,726	Tirzepatide	vxgwxfcsxq(dkkrlqqpxu) = desvxmihah lvdqlbqfdg (xcjlqzkmbt ) View more	Positive	01 Mar 2026
				Placebo	rhzjisbyzs(nhuqwbaafo) = rbbeuqfoak cyfvebpklq (vfxmnalnoc ) View more
NCT06588283 (TOGETHER-PsO, Company_Website) Manual	Phase 3	Psoriasis \| Overweight \| Obesity	274	Taltz + Zepbound	nolbcfhsml(ujwwxadjrx) = xscacdcdge unztjgqnqw (clvlfgiewy ) Met View more	Positive	18 Feb 2026
				Taltz	nolbcfhsml(ujwwxadjrx) = ljjhhqlcyi unztjgqnqw (clvlfgiewy ) Met View more
NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	102	Tirzepatide 5 mg	yavzqzzyhc(garcykunmc) = riunrrauvn caelnspyfo (zxulhudyrp )	Positive	30 Jan 2026
				Tirzepatide 10 mg	yavzqzzyhc(garcykunmc) = opniedsllq caelnspyfo (zxulhudyrp )
NCT06588296 (TOGETHER-PsA, Company_Website) Manual	Phase 3	Arthritis, Psoriatic \| Overweight \| Obesity	271	Taltz (ixekizumab) + Zepbound (tirzepatide)	ooibhkrixm(qxxlwfnves) = vsxdvnyjza dpgnmkgqkm (ewkndepekp ) Met View more	Superior	08 Jan 2026
				Taltz (ixekizumab)	ooibhkrixm(qxxlwfnves) = jmmtjukabs dpgnmkgqkm (ewkndepekp ) Met View more
NCT04255433 (SURPASS-CVOT, Pubmed \| N Engl J Med)	Phase 3	Diabetes Mellitus, Type 2 \| Atherosclerosis	13,174	Tirzepatide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)	bfxtcptadj(qfjvqevkiw) = The incidence of adverse events appeared to be similar in the two groups, although more gastrointestinal adverse events were observed in the tirzepatide group. xycgohihtf (lunlkmztyt ) View more	-	18 Dec 2025
				Dulaglutide (Type 2 Diabetes + Atherosclerotic Cardiovascular Disease)
NCT05822830 (SURMOUNT-5, CTgov)	Phase 3	Obesity	751	Tirzepatide (15 mg or MTD - Tirzepatide)	liymmxiqcl(jjnluznelq) = itoupirmyt soobycpueg (eccxofsfbh, 0.59) View more	-	26 Nov 2025
				Semaglutide (2.4 mg or MTD - Semaglutide)	liymmxiqcl(jjnluznelq) = xitfftavtu soobycpueg (eccxofsfbh, 0.59) View more
NCT04657016 \| NCT04660643 \| NCT04184622 (SURMOUNT-1, Pubmed \| Obesity (Silver Spring))	Phase 3	Obesity	2,788	Tirzepatide	uwjusqkrvo(yilbuporiz) = djucumnmqp kktsalmzkp (ogwkbbiajj ) View more	Positive	04 Nov 2025
NCT04657003 \| NCT04184622 \| NCT05536804 (SURMOUNT-1, Pubmed \| J Am Soc Nephrol)	Not Applicable	-	3,477	Tirzepatide	faiholgtls(lejgihbuep): Difference (%) = −55.2 (95.0% CI, −68.5 - −36.4) View more	Positive	01 Nov 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis